| September 27, 2012 |
Altor BioScience Awarded Two SBIR Phase I Grants by NCI for Research on its Novel IL-15 Super Agonists for Hematologic Cancers |
| April 30, 2012 |
Altor BioScience and the Melanoma Research Alliance to Co-Support Clinical Studies of Altor’s Novel IL-15 Superagonist for Metastatic Melanoma |
| August 17, 2011 |
Altor BioScience Awarded SBIR Phase I Grant by NCI for Research on its Novel IL-15 Super Agonist for Bladder Cancer |
| June 28, 2011 |
Florida Biologix Announces Manufacturing Agreement with Altor BioScience |
| May 23, 2011 |
Altor BioScience Awarded $3 MM SBIR Phase II Competing Renewal Grant by NHBLI to Complete a Second Phase 2 ALI/ARDS Clinical Trial for its Antibody-based Tissue Factor Antagonist, ALT-836 |
| February 16, 2011 |
Altor BioScience Awarded SBIR Phase I Grant by NIAID for HIV Research |
| January 24, 2011 |
Cancer play Altor stays majority-owned by individuals to pursue SBIRs Less VC, more SBIR |
| January 19, 2011 |
Altor BioScience Raises $10.3M Series D For Cancer Clinical Trials |
| November 3, 2010 |
S. Fla. biotechs get federal financial boost |
| September 25, 2009 |
Altor BioScience Awarded $3 MM SBIR Bridge Grant by NCI to Advance Clinical Trials for its Targeted Cancer Therapeutic ALT-801 |
| October 22, 2008 |
Altor BioScience is Awarded Grant from the Bill & Melinda Gates Foundation |
| September 10, 2008 |
Altor BioScience Licenses T-cell Receptors Targeting HIV and Hepatitis C from Massachusetts General Hospital |
| February 12, 2008 |
Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech |
| December 20, 2007 |
Altor BioScience Advances Clinical Trial for Targeted Cancer Therapeutic, ALT-801 |
| July 25, 2006 |
Altor BioScience Awarded Phase II SBIR Grant for Anti-Cancer Antibody Manufacture in Transgenic Plants |
| March 13, 2006 |
Altor BioScience Introduces STAR(TM) Multimer Reagents to Measure Disease-Specific Antigen Presentation |
| July 21, 2005 |
Altor BioScience Awarded SBIR Grant for Manufacturing Therapeutic Antibodies in Transgenic Plants |
| January 19, 2005 |
Altor BioScience Establishes Collaboration with Leading MGH Investigator to Develop TCR-based Agents to Detect and Treat HIV and HCV Infection |
| September 20, 2004 |
Altor Bioscience Receives Phase II SBIR Grant for Next-Generation Cancer Therapeutics |
| March 29, 2004 |
Altor BioScience Reports Advancements in its Soluble T-cell Receptor-Based Technology Programs |
| November 11, 2003 |
Altor Bioscience Reports Pre-Clinical Results Supporting Utility of Soluble T-Cell Receptor Fusions for Cancer Immunotherapy |
| September 26, 2003 |
Altor Bioscience Awarded NIH Grant to Expand Screening Program to Identify Orally Available Drugs to Treat Multiple Sclerosis |
| June 1, 2003 |
Altor Bioscience Receives SBIR Grant from NIAID for Development of Anti-Viral TCR Therapeutics |
| March 18, 2003 |
Altor Bioscience Issued New U.S. Patent for Innovative T-cell Receptor Technology |
